The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-mediated Human Pathological Cell Growth in Vitro and in Vivo

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2010 Dec 4

PMID 21127060

Citations 9

Authors

Annet Kirabo

Jennifer Embury

Robert Kiss

Timea Polgar

Meghanath Gali

Anurima Majumder

Kirpal S Bisht

Christopher R Cogle

Gyorgy M Keseru

Peter P Sayeski

Affiliations

Soon will be listed here.

Abstract

Using structure-based virtual screening, we previously identified a novel stilbenoid inhibitor of Jak2 tyrosine kinase named G6. Here, we hypothesized that G6 suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. We found that G6 inhibited proliferation of the Jak2-V617F expressing human erythroleukemia (HEL) cell line by promoting marked cell cycle arrest and inducing apoptosis. The G6-dependent increase in apoptosis levels was concomitant with increased caspase 3/7 activity and cleavage of PARP. G6 also selectively inhibited phosphorylation of STAT5, a downstream signaling target of Jak2. Using a mouse model of Jak2-V617F-mediated hyperplasia, we found that G6 significantly decreased the percentage of blast cells in the peripheral blood, reduced splenomegaly, and corrected a pathologically low myeloid to erythroid ratio in the bone marrow by eliminating HEL cell engraftment in this tissue. In addition, drug efficacy correlated with the presence of G6 in the plasma, marrow, and spleen. Collectively, these data demonstrate that the stilbenoid compound, G6, suppresses Jak2-V617F-mediated aberrant cell growth. As such, G6 may be a potential therapeutic lead candidate against Jak2-mediated, human disease.

Citing Articles

Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies.

Izuegbuna O Front Nutr. 2022; 9:1008893.

PMID: 36386899 PMC: 9643866. DOI: 10.3389/fnut.2022.1008893.

[Influence of clonal hematopoiesis on non-hematological diseases and aging processes].

Rieger M Inn Med (Heidelb). 2022; 63(11):1115-1125.

PMID: 36214849 PMC: 9549812. DOI: 10.1007/s00108-022-01409-6.

Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.

Kobayashi S, Vali S, Kumar A, Singh N, Abbasi T, Sayeski P Oncotarget. 2016; 7(24):35989-36001.

PMID: 27056884 PMC: 5094977. DOI: 10.18632/oncotarget.8540.

The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.

Baskin R, Park S, Keseru G, Bisht K, Wamsley H, Sayeski P PLoS One. 2014; 9(8):e105568.

PMID: 25162558 PMC: 4146502. DOI: 10.1371/journal.pone.0105568.

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.

Kirabo A, Park S, Wamsley H, Gali M, Baskin R, Reinhard M Am J Pathol. 2012; 181(3):858-65.

PMID: 22796437 PMC: 3432437. DOI: 10.1016/j.ajpath.2012.05.033.

References

Santos F, Kantarjian H, Jain N, Manshouri T, Thomas D, Garcia-Manero G . Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2009; 115(6):1131-6. PMC: 4081385. DOI: 10.1182/blood-2009-10-246363. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

Lacout C, Pisani D, Tulliez M, Gachelin F, Vainchenker W, Villeval J . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006; 108(5):1652-60. DOI: 10.1182/blood-2006-02-002030. View

Sandberg E, Ma X, He K, Frank S, Ostrov D, Sayeski P . Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005; 48(7):2526-33. DOI: 10.1021/jm049470k. View

Socolovsky M, Fallon A, Wang S, Brugnara C, Lodish H . Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999; 98(2):181-91. DOI: 10.1016/s0092-8674(00)81013-2. View

Larrosa M, Tomas-Barberan F, Espin J . Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem. 2004; 51(16):4576-84. DOI: 10.1021/jf030073c. View

Tyner J, Bumm T, Deininger J, Wood L, Aichberger K, Loriaux M . CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010; 115(25):5232-40. PMC: 2892953. DOI: 10.1182/blood-2009-05-223727. View

Geahlen R, McLaughlin J . Piceatannol (3,4,3',5'-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun. 1989; 165(1):241-5. DOI: 10.1016/0006-291x(89)91060-7. View

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A . Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010; 115(14):2919-27. PMC: 2854434. DOI: 10.1182/blood-2009-04-218842. View

10.

Sayyah J, Magis A, Ostrov D, Allan R, Braylan R, Sayeski P . Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol Cancer Ther. 2008; 7(8):2308-18. PMC: 2579271. DOI: 10.1158/1535-7163.MCT-08-0279. View

11.

Pardanani A, Lasho T, Smith G, Burns C, Fantino E, Tefferi A . CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009; 23(8):1441-5. DOI: 10.1038/leu.2009.50. View

12.

Baker S, Rane S, Reddy E . Hematopoietic cytokine receptor signaling. Oncogene. 2007; 26(47):6724-37. DOI: 10.1038/sj.onc.1210757. View

13.

Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

14.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

15.

Kimura Y . New anticancer agents: in vitro and in vivo evaluation of the antitumor and antimetastatic actions of various compounds isolated from medicinal plants. In Vivo. 2005; 19(1):37-60. View

16.

Levine R, Loriaux M, Huntly B, Loh M, Beran M, Stoffregen E . The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005; 106(10):3377-9. PMC: 1895066. DOI: 10.1182/blood-2005-05-1898. View

17.

Xing S, Wanting T, Zhao W, Ma J, Wang S, Xu X . Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008; 111(10):5109-17. PMC: 2384138. DOI: 10.1182/blood-2007-05-091579. View

18.

Wadleigh M, Tefferi A . Preclinical and clinical activity of ATP mimetic JAK2 inhibitors. Clin Adv Hematol Oncol. 2010; 8(8):557-63. View

19.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz S . Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005; 280(24):22788-92. PMC: 1201515. DOI: 10.1074/jbc.C500138200. View

20.

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View